# Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer

> **NCT01438112** · PHASE2,PHASE3 · TERMINATED · sponsor: **CG Oncology, Inc.** · enrollment: 22 (actual)

## Conditions studied

- Transitional Cell Carcinoma
- Bladder Cancer
- Carcinoma in Situ
- Carcinoma in Situ Concurrent With Papillary Tumors

## Interventions

- **BIOLOGICAL:** CG0070 Adenovirus Vector
- **OTHER:** Control Arm: Quadruple Choice

## Key facts

- **NCT ID:** NCT01438112
- **Lead sponsor:** CG Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-03
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Change in study design
- **Last updated:** 2021-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01438112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01438112, "Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01438112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*